Analystreport
Capricor Therapeutics Inc (NASDAQ: CAPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Last capricor therapeutics earnings: 11/8 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
| IMPACT SNAPSHOT | EVENT TIME: | CAPR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CAPR alerts
CAPR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting CAPRICOR THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
CAPR
NEWS
NEWS
- Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model[GlobeNewswire]
- Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day[GlobeNewswire]
- Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018[Accesswire]
- Capricor Therapeutics Inc (NASDAQ: CAPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock.[MarketBeat]
- Capricor Therapeutics Inc (NASDAQ: CAPR) was given a new $9.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.[MarketBeat]
- More
CAPR
SEC Filings
SEC Filings
- 4/26/18 - Form DEF
- 4/19/18 - Form CT
- 3/22/18 - Form 10-K
- CAPR's page on the SEC website
- More